Asia
CANbridge Pharmaceuticals Enters Service Agreements With WuXi Biologics, Baheal Medical
CANbridge Pharmaceuticals (HKG:1228) entered service procurement framework agreements with WuXi Biologics and Baheal Medical, according to a Tuesday Hong Kong bourse filing.Under the agreement, WuXi Biologics (HKG:2269) will provide contract research, development, and manufacturing organization services to CANbridge through 2028.Meanwhile, Baheal Medical will provide logistics, warehousing, and other supporting services through 2028.
HKG:1228HKG:2269
